Meta-Analysis of Sensorimotor Gating Deficits in Patients With Schizophrenia Evaluated by Prepulse Inhibition Test.

Szczegóły
Abstrakt

Tytuł:: Meta-Analysis of Sensorimotor Gating Deficits in Patients With Schizophrenia Evaluated by Prepulse Inhibition Test.
Autorzy:: San-Martin R; Center for Mathematics, Computation and Cognition, Universidade Federal do ABC, Santo André, Brazil.
Castro LA; Center for Mathematics, Computation and Cognition, Universidade Federal do ABC, Santo André, Brazil.
Menezes PR; Department of Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.; Population Mental Health Research Center, Universidade de São Paulo, São Paulo, Brazil.
Fraga FJ; Engineering, Modeling and Applied Social Sciences Center, Universidade Federal do ABC, Santo André, Brazil.
Simões PW; Engineering, Modeling and Applied Social Sciences Center, Universidade Federal do ABC, Santo André, Brazil.
Salum C; Center for Mathematics, Computation and Cognition, Universidade Federal do ABC, Santo André, Brazil.
Źródło:: Schizophrenia bulletin [Schizophr Bull] 2020 Dec 01; Vol. 46 (6), pp. 1482-1497.
Typ publikacji:: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
Język:: English
Imprint Name(s):: Publication: 2005- : Cary, NC : Oxford University Press
Original Publication: [Chevy Chase, Md., For sale by the Supt. of Docs., U. S. Govt. Print. Off. Washington]
MeSH Terms:: Prepulse Inhibition/*physiology
Schizophrenia/*physiopathology
Sensory Gating/*physiology
Humans
References:: Milbank Q. 2016 Sep;94(3):485-514. (PMID: 27620683)
Biol Psychiatry. 2002 Nov 1;52(9):863-73. (PMID: 12399139)
Syst Rev. 2016 Dec 5;5(1):210. (PMID: 27919275)
Psychopharmacology (Berl). 2001 Jul;156(2-3):234-58. (PMID: 11549226)
Schizophr Res. 2004 Aug 1;69(2-3):219-35. (PMID: 15469195)
Psychiatry Res. 2010 Jul 30;178(2):381-90. (PMID: 20483476)
Schizophr Res. 2018 Aug;198:52-59. (PMID: 29287625)
Neurosci Res. 2007 Sep;59(1):23-8. (PMID: 17692982)
Br J Psychiatry. 2019 Feb;214(2):103-112. (PMID: 30139394)
Biol Psychiatry. 2003 Jul 15;54(2):121-8. (PMID: 12873801)
Arch Gen Psychiatry. 1992 Mar;49(3):206-15. (PMID: 1567275)
Biol Psychiatry. 2005 Apr 1;57(7):817-20. (PMID: 15820241)
Schizophr Bull. 2009 Jan;35(1):244-55. (PMID: 18245063)
Schizophr Res. 2001 Apr 15;49(1-2):171-8. (PMID: 11343875)
BMC Psychiatry. 2018 Aug 16;18(1):258. (PMID: 30115023)
J Psychopharmacol. 2016 Nov;30(11):1072-1081. (PMID: 27539931)
Psychophysiology. 2008 Sep;45(5):876-82. (PMID: 18665868)
Schizophr Res. 2009 Dec;115(2-3):215-21. (PMID: 19846280)
Neurosci Res. 2009 Nov;65(3):259-62. (PMID: 19660506)
PLoS Med. 2009 Jul 21;6(7):e1000100. (PMID: 19621070)
Chin Med J (Engl). 2013 Feb;126(3):526-31. (PMID: 23422119)
Arch Gen Psychiatry. 2012 Dec;69(12):1216-24. (PMID: 23026889)
Front Behav Neurosci. 2016 Oct 18;10:202. (PMID: 27803654)
Biol Psychiatry. 2001 Sep 15;50(6):418-24. (PMID: 11566158)
Schizophr Res. 2012 May;137(1-3):203-11. (PMID: 22341200)
Span J Psychol. 2016 Mar 03;19:E8. (PMID: 26936103)
Psychiatry Res. 2011 Jul 30;188(2):208-16. (PMID: 21555157)
Biol Psychiatry. 2000 Jan 1;47(1):61-70. (PMID: 10650450)
Biol Psychiatry. 2008 Jan 1;63(1):17-23. (PMID: 17631867)
Schizophr Res. 2018 Aug;198:28-35. (PMID: 28732798)
Neuropsychiatr Dis Treat. 2016 Jan 06;12:57-67. (PMID: 26792993)
Hum Psychopharmacol. 2013 May;28(3):220-9. (PMID: 23553665)
Schizophr Res. 2007 Jan;89(1-3):225-31. (PMID: 17005374)
Neurosci Biobehav Rev. 2009 Sep;33(8):1157-67. (PMID: 19747594)
Arch Gen Psychiatry. 1999 Mar;56(3):277-81. (PMID: 10078506)
Schizophr Res. 2008 Apr;101(1-3):185-94. (PMID: 18262774)
Int J Neuropsychopharmacol. 2011 Aug;14(7):913-25. (PMID: 21294942)
Psychopharmacology (Berl). 2001 Jul;156(2-3):117-54. (PMID: 11549216)
J Psychopharmacol. 1998;12(4):330-7. (PMID: 10065906)
J Psychopharmacol. 2017 Aug;31(8):1035-1045. (PMID: 28648138)
J Int Med Res. 2012;40(4):1467-75. (PMID: 22971498)
Mol Psychiatry. 2016 Apr;21(4):547-53. (PMID: 26033243)
Am J Psychiatry. 1994 Mar;151(3):363-7. (PMID: 8109644)
Cogn Neuropsychiatry. 2016;21(2):156-67. (PMID: 26982087)
Biol Psychiatry. 2001 Feb 15;49(4):374-84. (PMID: 11239909)
Pharmacopsychiatry. 2011 May;44(3):102-8. (PMID: 21432751)
Swiss Med Wkly. 2002 Apr 6;132(13-14):159-65. (PMID: 12070788)
Schizophr Bull. 2016 Nov;42(6):1504-1516. (PMID: 27217271)
Biol Psychiatry. 2004 Mar 1;55(5):518-23. (PMID: 15023580)
Dialogues Clin Neurosci. 2006;8(1):9-16. (PMID: 16640109)
Schizophr Res. 2007 Mar;91(1-3):14-21. (PMID: 17276036)
Schizophr Bull. 2019 Sep 11;45(5):1092-1100. (PMID: 30388260)
Am J Psychiatry. 2002 Aug;159(8):1375-81. (PMID: 12153831)
Psychophysiology. 2003 Sep;40(5):684-701. (PMID: 14696723)
Psychiatry Res. 2006 Dec 7;145(2-3):137-45. (PMID: 17070928)
BMJ. 2016 Oct 12;355:i4919. (PMID: 27733354)
Schizophr Res. 2014 Feb;152(2-3):503-12. (PMID: 24405980)
Dental Press J Orthod. 2014 Jul-Aug;19(4):27-9. (PMID: 25279518)
Am J Psychiatry. 2002 Jun;159(6):1018-28. (PMID: 12042192)
PLoS One. 2012;7(7):e39434. (PMID: 22802938)
Biol Psychiatry. 2007 May 15;61(10):1204-7. (PMID: 17161386)
Psychopharmacology (Berl). 2001 Jul;156(2-3):194-215. (PMID: 11549223)
Psychophysiology. 2005 Jan;42(1):1-15. (PMID: 15720576)
Schizophr Res. 2002 May 1;55(1-2):129-37. (PMID: 11955972)
Psychophysiology. 1978 Jul;15(4):339-43. (PMID: 693742)
Biol Psychiatry. 1998 Oct 15;44(8):739-47. (PMID: 9798078)
Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2):72-5. (PMID: 21350428)
Psychiatry Res. 2006 Dec 1;148(2-3):75-92. (PMID: 17088049)
J Psychiatry Neurosci. 2013 Jan;38(1):34-42. (PMID: 22687247)
Schizophr Res. 2018 Aug;198:6-15. (PMID: 28549722)
Arch Gen Psychiatry. 2006 Dec;63(12):1325-35. (PMID: 17146007)
Biol Psychiatry. 2002 Oct 1;52(7):729-39. (PMID: 12372664)
Am J Psychiatry. 2007 Jan;164(1):61-5. (PMID: 17202545)
Psychol Methods. 2006 Jun;11(2):193-206. (PMID: 16784338)
Psychiatr Genet. 2005 Mar;15(1):61-5. (PMID: 15722959)
Am J Psychiatry. 1999 Jul;156(7):1046-51. (PMID: 10401450)
Acta Psychiatr Scand. 2015 Mar;131(3):185-96. (PMID: 25597383)
Biol Psychiatry. 2006 Mar 15;59(6):536-45. (PMID: 16139819)
Biol Psychiatry. 2000 Apr 1;47(7):662-9. (PMID: 10745060)
J Nerv Ment Dis. 2016 Dec;204(12):877-884. (PMID: 27483114)
Schizophr Res. 2005 Jul 1;76(1):1-23. (PMID: 15927795)
Asian J Psychiatr. 2012 Mar;5(1):54-7. (PMID: 26878949)
Psychiatry Res. 2014 Dec 15;220(1-2):535-40. (PMID: 25175914)
Schizophr Res. 2011 Aug;130(1-3):1-10. (PMID: 21645998)
J Clin Psychopharmacol. 2002 Aug;22(4):359-65. (PMID: 12172334)
Mol Psychiatry. 2005 Feb;10(2):201-7. (PMID: 15263904)
J Affect Disord. 2004 Aug;81(2):179-84. (PMID: 15306146)
Neurosci Biobehav Rev. 2016 Aug;67:57-78. (PMID: 26743859)
Front Neurosci. 2018 Sep 26;12:654. (PMID: 30319337)
Int J Neuropsychopharmacol. 2010 Nov;13(10):1383-95. (PMID: 20633319)
Schizophr Res. 2002 May 1;55(1-2):139-46. (PMID: 11955973)
Psychiatry Res. 2011 May 30;187(3):324-8. (PMID: 21397338)
J Psychiatr Res. 2016 Nov;82:155-62. (PMID: 27505440)
Brain Res. 1996 May 25;722(1-2):168-76. (PMID: 8813362)
J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):192-200. (PMID: 7876851)
Psychophysiology. 2004 May;41(3):401-6. (PMID: 15102125)
Neuropsychopharmacology. 2014 Dec;39(13):3000-8. (PMID: 24954063)
Psychopharmacology (Berl). 2001 Jul;156(2-3):216-24. (PMID: 11549224)
Schizophr Res. 2018 Aug;198:1-5. (PMID: 29525460)
J Psychiatr Res. 2013 Apr;47(4):445-52. (PMID: 23287742)
Behav Brain Res. 2005 Mar 7;158(1):159-66. (PMID: 15680203)
Schizophr Bull. 2014 May;40(3):642-52. (PMID: 23599252)
Biol Psychiatry. 1986 Jan;21(1):23-33. (PMID: 3080033)
Schizophr Res. 2009 Jul;112(1-3):86-90. (PMID: 19423298)
Psychiatry Res. 2010 Jul 30;178(2):236-43. (PMID: 20483176)
Eur Arch Psychiatry Clin Neurosci. 2004 Dec;254(6):415-21. (PMID: 15538598)
Psychiatry Res. 2012 Mar 30;196(1):1-8. (PMID: 22482796)
J Psychiatr Res. 2005 May;39(3):227-40. (PMID: 15725421)
Arch Gen Psychiatry. 2000 Jun;57(6):609-14. (PMID: 10839340)
Neuromolecular Med. 2015 Dec;17(4):423-30. (PMID: 26376812)
Am J Psychiatry. 1999 Apr;156(4):596-602. (PMID: 10200740)
Psychiatry Res. 2007 May 30;151(1-2):21-8. (PMID: 17382404)
Neurosci Res. 2008 Nov;62(3):187-94. (PMID: 18789980)
Eur Psychiatry. 2011 Jul-Aug;26(5):271-5. (PMID: 20542668)
Psychiatry Res. 2015 Aug 30;228(3):283-8. (PMID: 26154819)
Eur Arch Psychiatry Clin Neurosci. 2010 Dec;260(8):609-15. (PMID: 20112025)
Am J Psychiatry. 2000 Oct;157(10):1660-8. (PMID: 11007721)
BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120)
Contributed Indexing:: Keywords: PPI test; meta-regression; sensorimotor gating; systematic review
Entry Date(s):: Date Created: 20200608 Date Completed: 20211025 Latest Revision: 20240401
Update Code:: 20240401
PubMed Central ID:: PMC8061122
DOI:: 10.1093/schbul/sbaa059
PMID:: 32506125
: Czasopismo naukowe

Prepulse inhibition (PPI) of startle is an operational measure of sensorimotor gating that is often impaired in patients with schizophrenia. Despite the large number of studies, there is considerable variation in PPI outcomes reported. We conducted a systematic review and meta-analysis investigating PPI impairment in patients with schizophrenia compared with healthy control subjects, and examined possible explanations for the variation in results between studies. Major databases were screened for observational studies comparing healthy subjects and patients with schizophrenia for the prepulse and pulse intervals of 60 and 120 ms as primary outcomes, ie, PPI-60 and PPI-120. Standardized mean difference (SMD) and 95% confidence intervals (CI) were extracted and pooled using random effects models. We then estimated the mean effect size of these measures with random effects meta-analyses and evaluated potential PPI heterogeneity moderators, using sensitivity analysis and meta-regressions. Sixty-seven primary studies were identified, with 3685 healthy and 4290 patients with schizophrenia. The schizophrenia group showed reduction in sensorimotor gating for both PPI-60 (SMD = -0.50, 95% CI = [-0.61, -0.39]) and PPI-120 (SMD = -0.44, 95% CI = [-0.54, -0.33]). The sensitivity and meta-regression analysis showed that sample size, gender proportion, imbalance for gender, source of control group, and study continent were sources of heterogeneity (P < .05) for both PPI-60 and PPI-120 outcomes. Our findings confirm a global sensorimotor gating deficit in schizophrenia patients, with overall moderate effect size for PPI-60 and PPI-120. Methodological consistency should decrease the high level of heterogeneity of PPI results between studies.
(© The Author(s) 2020. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Informacja